Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Neurocrine Biosciences Moving Ahead With '854

Quarterly financial reports aren't all that important for pre-revenue biotechs, though they do give investors a chance to hear updated commentary about clinical trials, development plans, and so on. There were no blockbuster announcements from Neurocrine Biosciences (NASDAQ:NBIX) this quarter, but the company now has a clear path to begin the pivotal study of its most valuable 100%-owned asset. I would prefer to see/hear more about the company's efforts to get another drug into clinical development, but I continue to believe that Elagolix and NBI-98854 ('854) support a fair value above $17 today with a vital clinical update due late in the year or early next.

All Clear For Phase III In Tardive Dyskinesia

The most important update...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details